Corrected: BRIEF-Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28)
29/05/2026 11:06
CORRECTED-BRIEF-Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28) Adjusts the headline and bullets in a brief from May 28 to correct abbreviation error of a disease the medicine is meant to treat
May 29 (Reuters) - Sanofi SA SASY.PA:
FDA GRANTS PRIORITY REVIEW TO VENGLUSTAT NDA
TO PURSUE ADDITIONAL GLOBAL REGULATORY FILINGS FOR VENGLUSTAT IN 2026
VENGLUSTAT RECEIVED BREAKTHROUGH, FAST TRACK, AND ORPHAN DRUG DESIGNATIONS FOR GD3
IF APPROVED, VENGLUSTAT WOULD BECOME THE FIRST TREATMENT AVAILABLE IN THE UNITED STATES FOR THE PROGRESSIVE NEUROLOGICAL SYMPTOMS ASSOCIATED WITH GD3
Further company coverage: SASY.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes